Table 5.

Predictive value of the prognostic stratification schemes in Table 4 using TROG 96.01 trial data with 5-year prostate cancer-specific mortality (± one standard error) as an endpoint.

Author	Variable	Cutpoints, mortality, number of patients				Cutpoints, Mortality, Number of patients				c-index*
	PSADT	≥6 months				<6 months				0.675
Okotie et al. [8]		8 ± 2%				37 ± 4%
		n = 280 (58%)				n = 205 (42%)
D'Amico et al. [6]	PSADT	≥12 months				<12 months				0.598
Tollefson et al. [14]		6 ± 2%				26 ± 3%
		n = 138 (28%)				n = 347 (72%)
	GS	≤7				>7
	TTBF	>3 years		≤3 years		>3 years		≤3 years		0.694
Freedland et al. [10]†	PSADT	≥9 months	<9 months	≥9 months	<9 months	≥9 months	<9 months	≥9 months	<9 months
		3 ± 2%	13 ± 5%	5 ± 4%	35 ± 4%	0%	0%	29 ± 17%	38 ± 6%
		n = 139 (29%)	n = 57 (12%)	n = 41 (8%)	n = 151 (31%)	N = 14 (3%)	N = 7 (1%)	N = 7 (1%)	N = 69 (14%)
	GS	≤7				>7				0.654
Zhou et al. [13]	PSADT	≥3 months		<3 months		≥3 months		<3 months
		13 ± 2%		53 ± 8%		21 ± 5%		61 ± 12%
		n = 340 (70%)		n = 48 (10%)		n = 76 (16%)		n = 21 (4%)
Stephenson et al. [9]	GS	≤7				>7				0.647
	PSADT	>10 months		≤10 months		>10 months		≤10 months
		4 ± 2%		27 ± 3%		11 ± 8%		34 ± 6%
		n = 154 (32%)		n = 234 (48%)		n = 20 (4%)		n = 77 (16%)
Buyyounouski et al. [15]	GS	≤6				>6				0.682
	TTBF	≥1.5 years		<1.5 years		≥1.5 years		<1.5 years
		7 ± 2%		46 ± 9%		14 ± 3%		45 ± 5%
		n = 143 (29%)		n = 33 (7%)		n = 213 (44%)		n = 96 (20%)

n: number of TROG 96.01 subjects in study stratum; (X%): percentage of total number of TROG 96.01 subjects with biochemical failure (n = 485) in the study; GS: Gleason score; PSADT: PSA doubling time; TTBF: time to biochemical failure.

*Harrell's concordance index (higher c-index indicates that the model has a better predictive power).

^†Due to subject numbers, subsets with PSADT <3 months and >15 months are not presented in the Freedland study.